Top advances of the year: Developments of immunotherapy in cutaneous squamous cell carcinoma, 2023-2024

被引：0
作者：
Cunha, Mateus Trinconi [1 ]
Wallace, Neil [2 ]
Porceddu, Sandro [2 ,3 ]
Ferrarotto, Renata [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Div Thorac & Head & Neck Med Oncol, Houston, TX 77030 USA
[2] Peter MacCallum Canc Ctr, Dept Radiat Oncol, Melbourne, Vic, Australia
[3] Univ Melbourne, Melbourne, Vic, Australia
来源：
CANCER | 2025年 / 131卷 / 11期
关键词：
cutaneous squamous cell carcinoma; immune checkpoint inhibitors (ICI); immunosuppression; neoadjuvant; PD-1 inhibitors (PD1i); NONMELANOMA SKIN-CANCER; EFFICACY; HEAD; PEMBROLIZUMAB; MULTICENTER; MELANOMA; OUTCOMES; ADJUVANT; NECK;
D O I：
10.1002/cncr.35920
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Antibodies against PD-1 (PD1i), such as cemiplimab and pembrolizumab, have demonstrated significant efficacy in advanced, unresectable cutaneous squamous cell carcinoma (cSCC). These agents elicit durable responses in approximately 45% of patients, contributing to improved aesthetic, functional, and survival outcomes in a subset of individuals with advanced cSCC. This review highlights recent and ongoing research investigating the safety and efficacy of immune checkpoint inhibitors for cSCC in the curative intent perioperative settings, advanced/metastatic setting, and within the immunocompromised patient populations.
引用
收藏
页数：9
相关论文
共 58 条
[1]   United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019 [J].
Aggarwal, Pushkar ;
Knabel, Peter ;
Fleischer, Alan B., Jr. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (02) :388-395
[2]  
[Anonymous], About Basal and Squamous Cell Skin Cancer
[3]   Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma [J].
Blank, Christian U. ;
Rozeman, Elisa A. ;
Fanchi, Lorenzo F. ;
Sikorska, Karolina ;
van de Wiel, Bart ;
Kvistborg, Pia ;
Krijgsman, Oscar ;
van den Braber, Marlous ;
Philips, Daisy ;
Broeks, Annegien ;
van Thienen, Johannes, V ;
Mallo, Henk A. ;
Adriaansz, Sandra ;
ter Meulens, Sylvia ;
Pronk, Loes M. ;
Grijpink-Ongering, Lindsay G. ;
Bruining, Annemarie ;
Gittelman, Rachel M. ;
Warren, Sarah ;
van Tinteren, Harm ;
Peeper, Daniel S. ;
Haanen, John B. A. G. ;
van Akkooi, Alexander C. J. ;
Schumacher, Ton N. .
NATURE MEDICINE, 2018, 24 (11) :1655-+
[4]  
Bossi P, 2022, J CLIN ONCOL, V40
[5]   Treatment of Cutaneous Squamous Cell Carcinoma with Immune Checkpoint Inhibitors in Special Populations [J].
Bossi, Paolo ;
Lorini, Luigi .
DERMATOLOGY PRACTICAL & CONCEPTUAL, 2021, 11
[6]   Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer [J].
Bourhis, Jean ;
Stein, Alexander ;
de Boer, Jan Paul ;
Van den Eynde, Marc ;
Gold, Kathryn A. ;
Stintzing, Sebastian ;
Becker, Juergen C. ;
Moran, Michael ;
Schroeder, Andreas ;
Pennock, Gregory ;
Salmio, Satu ;
Esser, Regina ;
Ciardiello, Fortunato .
CANCER TREATMENT REVIEWS, 2021, 97
[7]  
Breukers S, 2023, J CLIN ONCOL, V41
[8]  
Center for Drug Evaluation and Research, 2019, FDA approves cosibelimab-ipdl for metastatic or locally advanced cutaneous squamous cell carcinoma
[9]   Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden [J].
Chalmers, Zachary R. ;
Connelly, Caitlin F. ;
Fabrizio, David ;
Gay, Laurie ;
Ali, Siraj M. ;
Ennis, Riley ;
Schrock, Alexa ;
Campbell, Brittany ;
Shlien, Adam ;
Chmielecki, Juliann ;
Huang, Franklin ;
He, Yuting ;
Sun, James ;
Tabori, Uri ;
Kennedy, Mark ;
Lieber, Daniel S. ;
Roels, Steven ;
White, Jared ;
Otto, Geoffrey A. ;
Ross, Jeffrey S. ;
Garraway, Levi ;
Miller, Vincent A. ;
Stephens, Phillip J. ;
Frampton, Garrett M. .
GENOME MEDICINE, 2017, 9
[10]   Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases [J].
Di Giacomo, Anna Maria ;
Danielli, Riccardo ;
Guidoboni, Massimo ;
Calabro, Luana ;
Carlucci, Dora ;
Miracco, Clelia ;
Volterrani, Luca ;
Mazzei, Maria Antonietta ;
Biagioli, Maurizio ;
Altomonte, Maresa ;
Maio, Michele .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (08) :1297-1306
123456